Send the link below via email or IMCopy
Present to your audienceStart remote presentation
- Invited audience members will follow you as you navigate and present
- People invited to a presentation do not need a Prezi account
- This link expires 10 minutes after you close the presentation
- A maximum of 30 users can follow your presentation
- Learn more about this feature in our knowledge base article
Do you really want to delete this prezi?
Neither you, nor the coeditors you shared it with will be able to recover it again.
Make your likes visible on Facebook?
You can change this under Settings & Account at any time.
iTalk Part 1
Transcript of iTalk Part 1
November 30, 2012 iTalk Time to Shaikh it Up EDUCATOR MANAGER MEDICAL EXPERT RESEARCHER ELECTION 2012 1. Teach to the Learner's Z ne of Proximal Development
(Show the Forest, then the Trees, then the Twigs) Orientation Application Innovation Survive Decide Devise Experiences
Evaluations Handbook Portal Research Club 2. Replace "Self-Directed" with "Guided Self-Directed."
(Make it Easy to do the Right Thing) Algorithm Heuristic Mystery 3. The Best Time to Learn Something is Right Before You Need to Use it
(And the Best Time for Feedback is Right After) What's Next? Develop a ME-Learning Curriculum Multimedia Lectures
Core Literature Archive
Website and App Develop Personalized Evaluations Challenges Workflow Gap Analysis Demo What's Next? Documentation
Complexity Database CPOE Website Mobile Structured
Notes Roles Rare Tumors Are Common Common Tumors Are (Becoming) Rare Rare Tumors Have the Longest Discussions Rare Tumors Have Important "Reduction of Therapy" Questions Rare Tumors Have Exciting Biostatistical Challenges Rare Tumors Are Entering the Biological Era Rare Tumors Make Good Fellows' Projects Rare Tumors Aren't Rare for the Patient Pooled Database, International Collaboration, Non-Inferiority, "Pick the Winner", Bayesian and Meta-Analytic, Unconventional P-value DICER1 in PPB
miRNA in GCT
Cisplatin Pharmacogenomics ...Rare Tumor Bowling! WHAT'S NEXT? General Expertise in Solid Tumors
Focused Expertise in Rare Tumors
Clinical Research & Trials Q. How common are difficult and traumatic LPs? Q2. What are the Consequences of TLPs? Q3. What are the Risk Factors for TLPs? Q4. Is There a Better Way? Q5. Can it Be Done by Pediatric Oncologists? Q6. What's Next? "Section Program Director" Standardization
Regional Network Continue to:
Ask New Questions
Develop Sound Methods
Find Innovative Answers